O-27: Treatment of Ovarian HyperstimulationSyndrome Using Gonadotropin Releasing HormoneAntagonist

Background: Ovarian hyperstimulation syndrome is the most serious complication of ovarian stimulation. This novel study aimed to describe an outpatient treatment protocol for ovarian hyperstimulation syndrome (OHSS) that results in rapid normalization of symptoms with minimal side effects. Materials and Methods: A prospective study was undertaken at Infertility department of Shariati Hospital affiliatedto Tehran University of Medical Sciences during 2009-2010. Ten consecutive patients undergoing controlled ovarian hyperstimulation after long protocol pituitary down regulation, diagnosed with OHSS, who presented after oocyte retrieval but without embryo transfer, were enrolled. All embryos were frozen and each patient was treated with the daily 0.25 mg(sc) Cetrotide for two consecutive days. Weight changes, days to resolution of clinical symptoms, side effects of the treatment protocol, and whether or not acute care or hospitalization was necessary were evaluated. They were compared with other ten OHSS patients (control group) managing with conservative measures and dopamine agonist (cabergoline).Results: Interesting results of this study revealed that the average time to resolution of clinical symptoms with Cetrotide was shorter. No side effects were reported and no patients required acute care or hospitalization. The most rapid weight loss was within the first week of treatment. The Patents’ satisfaction with Cetrotide was noticeable.Conclusion: GnRH antagonists, when given at the time of diagnosis of OHSS, appear to work rapidly and effectively to diminish the clinical symptoms of the disease. May be it is attributed to its luteolytic effect. Due to debate about safety of these drugs during pregnancy it is reasonable to freeze the embryos for future cycle